饮食维生素E摄入量在与代谢功能障碍相关的脂肪性肝病和所有原因/特定原因死亡率中
Donghee Kim1, Pojsakorn Danpanichkul2, Karn Wijarnpreecha3,4
1Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.
European journal of gastroenterology & hepatology
|September 10, 2025
概括
与代谢功能障碍相关的脂肪性肝病 (MASLD) 患者的较高饮食维生素E摄入量与全因死亡风险降低有关. 这一发现表明,维生素E在这种患者群体中具有潜在的保护作用.
科学领域:
- 营养与饮食学 营养与饮食学
- 肝病学 肝病学是一种肝病学.
- 流行病学 流行病学
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一个日益严重的公共卫生问题.
- 饮食因素,包括维生素E,可能会影响MASLD的进展和患者的结果.
- 了解MASLD中营养摄入量和死亡率之间的关系对于临床管理至关重要.
研究的目的:
- 为了检查饮食维生素E摄入量与美国人口中MASLD的死亡率之间的关联.
- 调查这种关联是否在各个子组之间存在差异.
主要方法:
- 利用了2007-2014年美国国家健康和营养检查调查的数据.
- 包括到2019年的死亡率随访 (中位数为8.6年).
- 使用考克斯回归模型分析MASLD患者的维生素E摄入量和死亡风险.
主要成果:
- 较高的饮食维生素E摄入量与MASLD患者全因死亡风险的降低相关 (HR:0.68,95%CI:0.50-0.94对于Q4和Q1).
- 保护性关联在老年人,男性和非西班牙裔白人中更为明显.
- 趋势表明,随着更高的维生素E摄入量,与癌症相关的死亡率降低.
结论:
- 饮食中较高的维生素E摄入量与MASLD患者全因死亡风险较低有关.
- 维生素E可能在管理MASLD和改善生存结果方面发挥有益作用.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Vitamins
2.3K
Vitamins, derived from the Latin word for life, are essential organic substances required in small quantities for optimal growth and overall well-being. Unlike other organic nutrients, vitamins don't act as sources of energy or building materials but rather facilitate these nutrients' utilization by the body. Vitamins are predominantly coenzymes, assisting enzymes in specific chemical actions, like the oxidation of glucose for energy involving B vitamins. Most vitamins are not produced...
2.3K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
257
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257
Lipids: Dietary Sources and Requirements
1.8K
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ...
1.8K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
216
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
216
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
217
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
217


